Skip to main content
Equibles
NAGE logo

NAGE · Niagen Bioscience, Inc. · Investor Relations

Track NAGE — free

Use NAGE with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NAGE.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.79 +0.00 (+0.00%)
Russell 2000 member Rebalance outlook locked
Market Cap
$241.33M
Shares
79.13M
Volume · Oct 2 1.57M Avg daily vol (3M) 599K

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-10-01 Niagen Bioscience Puts 25 Years of NAD+ Science Behind "Don't Get Old. Age Better.®” a New Campaign for its Niagen® Brand Featuring Legendary Surfer Kelly Slater
2026-09-30 Niagen Bioscience Announces Start-Up Agreement With Mass General Brigham (MGB) Investigators For First-Of-Its-Kind Healthy Aging Clinical Trial
2026-09-21 Newly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with Nicotinamide Riboside (NR) Improves Pregnancy Outcomes
2026-09-17 Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth
2026-09-10 Niagen Bioscience to Present at Canaccord Genuity’s Well Summit
2026-09-02 Niagen Bioscience to Present at Longevity Investors Conference
2026-08-26 Niagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit
2026-08-20 Niagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam’s Club
2026-08-12 Niagen Bioscience to Present at the 17th Annual Midwest IDEAS Investor Conference
2026-08-06 Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence
2026-08-04 Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results
2026-08-03 Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168
2026-07-28 Niagen Bioscience Announces a Newly Published Analysis of Past Clinical Studies Demonstrating Niagen® (Patented Nicotinamide Riboside, NR) Supplementation Improved a Muscle-Specific Marker of Biological Aging
2026-07-27 Niagen Bioscience to Present at Canaccord Genuity’s 46th Annual Growth Conference
2026-07-21 Niagen Bioscience to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
2026-07-16 Niagen Bioscience Appoints Abhijit Kale, Ph.D., as Senior Director of Global External Research
2026-07-13 Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)
2026-07-09 Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026
2026-07-08 Niagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases
2026-06-03 Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference
2026-06-02 Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science
2026-05-08 Niagen Bioscience Announces Participation in Upcoming Investor Conferences
2026-05-06 Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results
2026-05-04 Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering
2026-04-28 Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™

Past events

Date Event Type
2026-09-09 Nasdaq X LD Micro Inaugural SF Summit Conference
2026-08-27 Midwest IDEAS Investor Conference Conference
2026-08-11 Canaccord Genuity 46th Annual Growth Conference Conference
2026-08-04 Niagen Bioscience Second Quarter 2026 Earnings Conference Call Earnings call
2026-07-15 KCSA Strategic Communications Fireside Chat with Rob Fried, Chief Executive Officer, Niagen Bioscience Event
2026-06-11 East Coast IDEAS Conference Presentation Conference
2026-05-06 Niagen Bioscience First Quarter 2026 Earnings Conference Call Earnings call
2026-03-23 38th Annual ROTH Conference: Technologies Advancing Healthy Aging Panel Conference
2026-03-04 Niagen Bioscience Fourth Quarter 2025 Earnings Conference Call Earnings call
2026-01-15 2nd Annual Lytham Partners Investor Summit Event
2025-11-04 Niagen Bioscience Third Quarter 2025 Earnings Conference Call Earnings call
2025-08-12 Canaccord Genuity 45th Annual Growth Conference Conference
2025-08-06 Niagen Bioscience Second Quarter 2025 Earnings Conference Call Earnings call
2025-06-09 Oppenheimer’s 25th Annual Consumer Growth and E-Commerce Conference Conference
2025-05-07 Niagen Bioscience First Quarter 2025 Earnings Conference Call Earnings call
2025-03-04 ChromaDex Fourth Quarter 2024 Earnings Conference Call Earnings call
2024-10-31 ChromaDex Third Quarter 2024 Earnings Conference Call Earnings call
2024-08-07 ChromaDex Second Quarter 2024 Earnings Conference Call Earnings call
2024-06-11 Renmark Virtual Non-Deal Roadshow Presentation Presentation
2024-05-08 ChromaDex First Quarter 2024 Earnings Conference Call Earnings call
2024-03-06 ChromaDex Fourth Quarter 2023 Earnings Conference Call Earnings call
2024-02-12 ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series Event
2023-11-14 ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series Event
2023-11-08 ChromaDex Third Quarter 2023 Earnings Conference Call Earnings call
2023-08-16 ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series Event

Source: https://investors.niagenbioscience.com/overview/default.aspx

Key facts CIK 1386570 CUSIP 171077407 13F (30d) 5 filings 4 filers Visit website Investor relations